Price List - Myqorzo - Cardiovascular Agents Miscellaneous - NA.xlsx
XLSX spreadsheet 47 KB Posted
- Solicitation number
- HT9402-26-Q-9202
- Issued by
-
Defense Health Agency
About this file
This is a pricing template and formulary appendix for the Department of War (DoW) Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) for the May 2026 P&T Committee meeting. The file establishes the pricing structure for Myqorzo, a cardiovascular agent in the miscellaneous cardiovascular agents class, scheduled for review at the May 6-7, 2026 P&T Committee meeting. The template is organized into multiple appendices addressing different contract vehicles and pricing methodologies: the BPA UF appendix contains ten newly approved drug entries with formulary scenarios (Uniform Formulary and Non-Formulary categories) requiring price per NDC package size and price per unit submissions; the ADP (non-FAMP Discount) appendix includes ten drug entries with Tier 2 and Tier 3 TRICARE retail refund scenarios requiring non-FAMP pricing, additional offered refund percentages, and federal ceiling price information; and the ADP (WAC Discount) appendix provides ten drug entries using Wholesale Acquisition Cost-based pricing with discount percentages for Tier 2 and Tier 3 categories.
The RFQ response deadline is March 26, 2026, with a mandatory pre-quotation teleconference scheduled for March 11, 2026. Manufacturers must submit quotes with the Quote Submission Checklist and fully executed signature pages. Key formulary notes indicate that the agent will be reviewed quarterly per 32 CFR 199.21(g)(5), with Prior Authorization potentially applicable. The P&T Committee may recommend preferential status treating non-generic agents as generics (Tier 1) for cost-sharing purposes or recommend complete exclusion from the TRICARE pharmacy benefit program. For BPA submissions, price per unit must remain consistent across all package sizes within each dispensing venue. For ADP (non-FAMP) submissions, the total calculated refund is derived from the non-FAMP price plus an additional refund percentage applied to the Federal Ceiling Price, with the quoted percentage remaining static throughout the agreement term while the calculated refund may vary annually based on updated non-FAMP data. For ADP (WAC) submissions, the quoted WAC discount percentage remains static during the agreement term.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Cardamyst - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Sdamlo - Calcium Channel Blocking Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Pivya -Antibiotics - Beta-lactams.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9202 NAD.pdf | ||
| Price List - Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction.xlsx | XLSX spreadsheet | |
| Price List - Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Ontralfy - Skeletal Muscle Relaxants and Combinations - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 263CANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 263CANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | |||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | |||
| DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 |
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Submission Checklist and fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOW Uniform Formulary Class: | CARDIOVASCULAR AGENTS MISCELLANEOUS | P&T Committee Meeting: | May 6-7, 2026 | ||
| DOW Uniform Formulary Subclass: | N/A | Quotes due: | March 26, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 263CANAG1T21M | Tier 2 | 1 or more | |
| 263CANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .